Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
NCT03912337 · Amgen · PHASE4 · terminated · last registry update 2022-07-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Terminated \[Study would not complete enrollment target until 2026 with results available in 2027. The information will not be useful at that time.\]” | – | Registry record, Amgen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CALCRL within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-05-31Results posted on the registry: AbbVie, Ubrogepant 100 mg + Placebo (NCT04492020)
- 2023-05-24Results posted on the registry: Allergan, Atogepant (NCT04829747)
- 2023-05-16Phase 3 first posted: AbbVie, Atogepant + Placebo for Atogepant (NCT05861427)
- 2023-04-12Phase 3 first posted: Pfizer, Rimegepant + Placebo (NCT05810038)
- 2023-03-16Results posted on the registry: Pfizer, Zavegepant (BHV-3500) (NCT04408794)
- 2023-03-16Results posted on the registry: Pfizer, Zavegepant + Placebo (NCT04571060)
- 2023-02-28Phase 3 first posted: AbbVie, Atogepant + Placebo for Atogepant (NCT05748483)
- 2023-02-17Results posted on the registry: Mayo Clinic, Erenumab (NCT04303845)
- 2023-02-17Also stopped (terminated): Mayo Clinic, Erenumab (NCT04303845)
- 2023-02-14Results posted on the registry: Allergan, Atogepant 30 mg + Atogepant 60 mg (NCT03855137)
- 2023-02-03Phase 3 first posted: AbbVie, Atogepant + Placebo-Matching Atogepant (NCT05711394)
- 2023-02-01Phase 3 first posted: AbbVie, Atogepant (NCT05707949)
- 2022-10-25Results posted on the registry: Amgen, AMG334 + Oral Prophylactic (NCT03927144)
- 2022-10-13Results posted on the registry: Pfizer, Zavegepant + Zavegepant matching placebo (NCT03872453)
- 2022-10-05Results posted on the registry: Merle Diamond, Erenumab-Aooe 140 MG/ML [Aimovig] (NCT04465357)
- 2022-07-14Phase 3 first posted: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT05458011)
- 2022-06-01Phase 3 first posted: Pfizer, Rimegepant + Placebo (NCT05399485)
- 2022-06-01Phase 3 first posted: Pfizer, Rimegepant 25 MG + Rimegepant 75 MG (NCT05399459)
- 2022-05-12Phase 3 first posted: Pfizer, Rimegepant 75mg Orally Disintegrating Tablets (ODT) (NCT05371652)
- 2022-05-12Results posted on the registry: Allergan, Atogepant (NCT03939312)
- 2022-04-13Results posted on the registry: David True, Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY] (NCT04461795)
- 2022-03-22Results posted on the registry: Eli Lilly and Company, Galcanezumab + Erenumab (NCT04294147)
- 2022-03-02Phase 3 first posted: Pfizer, Rimegepant + Placebo (NCT05262517)
- 2022-02-28Also stopped (withdrawn): Mayo Clinic, Fremanezumab + Placebo (NCT04334408)
- 2022-02-22Also stopped (withdrawn): Mayo Clinic, Erenumab (NCT04920331)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision